Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKaba, S. E.en
dc.contributor.authorKyritsis, A. P.en
dc.contributor.authorHess, K.en
dc.contributor.authorYung, W. K.en
dc.contributor.authorMercier, R.en
dc.contributor.authorDakhil, S.en
dc.contributor.authorJaeckle, K. A.en
dc.contributor.authorLevin, V. A.en
dc.rightsDefault Licence-
dc.subjectAdenocarcinoma/drug therapy/secondaryen
dc.subjectAge Factorsen
dc.subjectAntineoplastic Combined Chemotherapy Protocols/*therapeutic useen
dc.subjectBrain Neoplasms/*drug therapy/secondaryen
dc.subjectBreast Neoplasms/pathologyen
dc.subjectCarcinoma, Non-Small-Cell Lung/drug therapy/secondaryen
dc.subjectCarcinoma, Small Cell/drug therapy/secondaryen
dc.subjectDisease Progressionen
dc.subjectFluorouracil/administration & dosageen
dc.subjectHydroxyurea/administration & dosageen
dc.subjectLomustine/administration & dosageen
dc.subjectLung Neoplasms/pathologyen
dc.subjectMiddle Ageden
dc.subjectMitolactol/administration & dosageen
dc.subjectProcarbazine/administration & dosageen
dc.subjectProspective Studiesen
dc.subjectThioguanine/administration & dosageen
dc.titleTPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumorsen
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.abstractPURPOSE: To evaluate a combination of thioguanine, procarbazine, dibromodulcitol, CCNU (CCNU), fluorouracil, and hydroxyurea (TPDC-FuHu), designed to improve the efficacy of CCNU, in the treatment of recurrent metastatic brain tumors. PATIENTS AND METHODS: One hundred fifteen patients with progressive or recurrent metastatic brain tumors that failed to respond to surgery and/or radiation therapy were enrolled onto a multicenter prospective study between 1989 and 1995. Patients received TPDC-FuHu in a repeated cycle every 6 weeks until recurrence or until they completed six courses. RESULTS: Ninety-seven patients were assessable at the end of the study. Forty-eight had lung cancer (39 non-small-cell [NSCLC] and nine small-cell [SCLC]), 28 had breast cancer, nine had melanoma, and 12 had adenocarcinoma of different origins (three colon, two kidney, one bladder, one stomach, and five of unknown origin). The response and stable disease (SD) rate (overall response rate) was 52%, 66%, 60%, and 22% in patients with NSCLC, SCLC, breast cancer, and melanoma, respectively. Median time to progression (MTP) was 12, 26, 12, and 6 weeks, respectively, for the four groups. Side effects were mild to moderate in the majority of patients. Severe myelosuppression (grade 4) occurred in only 11% of the patients. CONCLUSION: TPDC-FuHu chemotherapy is an active treatment against recurrent brain metastases from breast cancer and SCLC, and to a lesser extent from NSCLC. This regimen is well tolerated and has acceptable toxicity.en
heal.journalNameJ Clin Oncolen
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
There are no files associated with this item.

This item is licensed under a Creative Commons License Creative Commons